Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
A one arm study to assess the pharmacokinetics, safety and effectiveness of tacrolimus in stable liver transplant patients converted from a tacrolimus (Prograf®) based immunosuppression regimen to a modified release tacrolimus based immunosuppression regimen.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is currently receiving Prograf ® based immunosuppressive therapy for liver transplantation.
Patient has stable whole blood trough level concentrations of Prograf® and is clinically stable
You may not be if
Patient has previously received an organ transplant other than a liver
Patient is currently receiving sirolimus immunosuppression therapy.
